Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase

INTRODUCTION: The incidence of grade 3–4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hematol Transfus Cell Ther
Main Authors: Moura, Muriel Silva, Benevides, Thais Celi Lopes, Delamain, Marcia Torresan, Duarte, Gislaine Oliveira, Percout, Priscila Oliveira, Dias, Maria Almeida, Zulli, Roberto, Souza, Carmino Antonio de, Lorand-Metze, Irene, Pagnano, Katia Borgia Barbosa
Formato: Artigo
Idioma:Inglês
Publicado em: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6978532/
https://ncbi.nlm.nih.gov/pubmed/31395459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.htct.2019.03.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados